Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | LSS | P48449 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124734 | 0.95 | KCNH2 (0.57) | KCNH2CYP19A1THRBLSS | |
| SCHEMBL3129028 | 0.95 | KCNH2 (0.57) | KCNH2CYP19A1THRBLSS | |
| SCHEMBL3128798 | 0.95 | THRB (0.56) | KCNH2CYP19A1THRBLSSHTR7 | |
| SCHEMBL3126734 | 0.93 | KCNH2 (0.50) | KCNH2CYP19A1THRBLSSHTR7 | |
| SCHEMBL3119466 | 0.90 | KCNH2 (0.49) | KCNH2CYP19A1THRBHTR7 | |
| SCHEMBL3132793 | 0.89 | KCNH2 (0.52) | KCNH2CYP19A1THRBLSSCNR1 | |
| SCHEMBL3130292 | 0.89 | KCNH2 (0.55) | KCNH2CYP19A1THRBHTR7 | |
| SCHEMBL3125156 | 0.88 | KCNH2 (0.48) | KCNH2CYP19A1THRBLSSCNR1 | |
| SCHEMBL3119501 | 0.88 | HTR7 (0.57) | KCNH2CYP19A1THRBLSSHTR7 | |
| SCHEMBL4498694 | 0.87 | KCNH2 (0.52) | KCNH2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765832-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | claimed |
| WO-2005123748-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | claimed |
| US-7648985-B2 | Oxabispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-01-19 | — | — | US | disclosed |
| US-20090270383-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| US-20090005558-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| EP-1765832-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123748-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270383-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 8/4885CYP19A1 2130/4885THRB 486/4885 |
| US-20090005558-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 8/4885CYP19A1 2130/4885THRB 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.